GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » Capex-to-Operating-Cash-Flow

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) Capex-to-Operating-Cash-Flow : -0.03 (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Dawnrays Pharmaceutical (Holdings)'s Capital Expenditure for the six months ended in Dec. 2024 was HK$1.48 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2024 was HK$52.05 Mil.

Hence, Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2024 was -0.03.


Dawnrays Pharmaceutical (Holdings) Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) Capex-to-Operating-Cash-Flow Chart

Dawnrays Pharmaceutical (Holdings) Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.75 1.03 0.52 0.63 0.80

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 1.02 0.10 1.03 -0.03

Competitive Comparison of Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow falls into.


;
;

Dawnrays Pharmaceutical (Holdings) Capex-to-Operating-Cash-Flow Calculation

Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-187.51) / 235.101
=0.80

Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (1.479) / 52.045
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Dawnrays Pharmaceutical (Holdings) Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Dawnrays Pharmaceutical (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, Manufacture and sale of finished drugs and Manufacture and sale of intermediates and bulk medicines. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Executives
Li Kei Ling
Hung Yung Lai
Leung Hong Man
Fortune United Group Limited 2101 Beneficial owner
Hunwick International Limited 2201 Interest of corporation controlled by you
Keysmart Enterprises Limited 2201 Interest of corporation controlled by you
Iu Pun 2202 Interest of your spouse
Li Tung Ming
Fmr Llc 2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines